Recursion Pharmaceuticals, Inc. (RXRX) stock
RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/309% below fair value
$2.72−0.18 (-6.37%)
Close on Nov 17, 2026Market cap $1.46BP/E –Yield –
Recursion Pharmaceuticals market cap
Market capitalization is the share price multiplied by the number of shares outstanding.
Recursion Pharmaceuticals's market cap was $1.92B on Nov 11, 2026, against $2.28B a year earlier. Over the last 5 years it ranged from $911.18M to $3.15B, with a median of $1.90B.
Market Cap at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.92B | -4.7% |
| 2025 | Dec 31, 2025 | $2.01B | +4.0% |
| 2024 | Dec 31, 2024 | $1.93B | -9.3% |
| 2023 | Dec 29, 2023 | $2.13B | +58.9% |
| 2022 | Dec 30, 2022 | $1.34B | -53.5% |
| 2021 | Dec 31, 2021 | $2.89B | – |
See a number that looks wrong?